Interv Akut Kardiol. 2012;11(2):53-56

Short-term clinical and echocardiographic results of patients follow-up after TAVI

Hana Línková, Jiří Knot, Petr Toušek, Viktor Kočka
III. interní &ndash, kardiologická klinika FN KV a 3. LF UK Praha

Introduction: The aortal stenosis is the most frequent valve abnormality in adult. According to Euro Hear Survey one third of patients

with significant AS were contraindicated for surgical aortic valve replacement (AVR) due to a high risk of surgery. The percutaneous

aortic valve replacement (TAVI) is the alternative treatment. Currently, the patients contraindicated for AVR due to a high risk of open

heart surgery are indicated for TAVI.

Goal: To evaluate the clinical and echocardiographic follow-up parameters for patients after TAVI.

Methods: 55 patients (including 30 women) underwent TAVI in our hospital since April 2009. In 98.2 % this procedure was successful.

The patients were checked including echocardiography one to six months after this treatment. NYHA classification was applied as the

clinical criterium.

Results: Peri-procedural mortality was 1.8 %. The mortality after 30 days and after six months was 4.1 % and 7.7 %, respectively. Fourteen and

25.6 % were hospitalized as a results of checkup one and six months after the TAVI, respectively. After six months the majority of patients were

classified with NYHA I or II. Before the treatment the average EF was 51.18 ± 10.03, PG max. on the aortic valve was 68.49 ± 19.7 mmHg, Vmax.

3.97m/s± 0.56. After six months the EF was 54.1 ± 9.2 %, Vmax 1.89 ± 0.47 m/s, PG max. 14.35 ± 7.04 mmHg. We did not register any significant

aortic regurgitation (AR). We observed non-significant AR (1/4) and mild AR (2/4) in 40 % and 16 % of patients, respectively.

Conclusion: Our study performed on a small amount of patients confirm that TAVI is an efficient and save treatment for patients with

significant symptomatic AS and a high risk of surgery. Echocardiographic and clinical results are comparable with published data. In addition,

this treatment is the only alternative for patients contraindicated for surgery valve replacement due to the high risk of surgery.

Keywords: aortic stenosis, transcatheter aortic valve implantation, mortality, morbidity, complications

Published: April 23, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Línková H, Knot J, Toušek P, Kočka V. Short-term clinical and echocardiographic results of patients follow-up after TAVI. Interv Akut Kardiol. 2012;11(2):53-56.
Download citation

References

  1. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 Guidenlines for the management of patiens with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practise Guidelains (Writing Committee to Revise the 1998 Guidelines for the Management of Patient With Valvular Heart Disease), J Am Coll Cardiol 2006; 48: 1-148. Go to original source... Go to PubMed...
  2. Vahanian A, Baumgartner H, Bax J, et al. and Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology, Guidelines for the management of valvular heart disease, Eur. Heart J 2007; 28: 230-268. Go to original source...
  3. Popelová J, Benešová M, Brtko M, a kol. Doporučené postupy pro léčbu chlopenních srdečních vad v dospělosti, Cor Vasa 2007; 49(Suppl 11): 6-46.
  4. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002; 106: 3006-3008. Go to original source... Go to PubMed...
  5. Cribier A, Eltchaninoff H, Tron C, Bauer F, Gerber L. Percutaneous implantation of aortic valve prosthesis in patients with calcific aortic stenosis: technical advances, clinical results and future strategies. J Invasive Cardiol. 2006; 19: S88-S96. Go to original source...
  6. Lichtenstein SV, Cheung A, Ye J, Thompson CR, Carere RG, Pasupati S, Webb JG. Transapical transcatheter aortic valve implantation in man. Circulation. 2006; 114: 591-596. Go to original source... Go to PubMed...
  7. Webb JG, Pasupati SJ, Humphries K, Thompson C, Altwegg L, Moss R, Sinhal A, Carere RG, Munt B, Ricci D, Ye J, Cheung A, Lichtenstein SV. Percutaneous transarterial aortic valve replacement in selected high risk patients with aortic stenosis. Circulation. 2007; 116: 755-763. Go to original source... Go to PubMed...
  8. Walther TFV, Kempfert J, Borger MA, Fassl J, Chu MWA, Schuler G, Mohr FW. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg. 2008; 33: 983-988. Go to original source... Go to PubMed...
  9. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, Sauren B, Mohr FW, Zickmann B, Ivesen S, Felderhoff T, Cartier R, Bonan R. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second and current third generation self-expanding CoreValve prosthesis: device success and 30 day outcome. J Am Coll Cardiol. 2007; 50: 69-76. Go to original source... Go to PubMed...
  10. Smith CR. Transcatether aortic valve implantation versus surgical aortic valve replacement in high risk patient with aortic stenosis.. The randomized PARTNER trial. Presented at American College of Cardiology Annual Scientific Session/ i2 Summit; April 3, 2011; New Orleasn, LA.
  11. Leon MB, Piazza N, Nikolsky E, et al. Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials; A Consensus Report From the Valve Academic Research Consortium.J.Am.Coll Cardiol. 2011; 57: 253-269. Go to original source... Go to PubMed...
  12. Webb JG, Altwegg L, Boone RH, et al. Transcatheter Aortic Valve Implantation, Impact on Clinical and Valce related Outcomes. Circulation 2009; 119: 3009-3016. Go to original source... Go to PubMed...
  13. Vojáček J, Šťástek J, Bis J. Dvouleté zkušenosti s transkutánní implantací aortální chlopně v Komplentním kardiocentru Hradec Králové, Intervenční akutní kardiologie 2011; 10(1): 9-12.




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.